Population Pharmacokinetics of Obinutuzumab (GA101) in Chronic Lymphocytic Leukemia (CLL) and Non-Hodgkin's Lymphoma and Exposure–Response in CLL

Treatment regimens involving obinutuzumab (GA101) demonstrated increased efficacy to rituximab in clinical trials for non-Hodgkin's lymphoma (NHL) and chronic lymphocytic leukemia (CLL). However, the pharmacokinetic (PK) properties and the exposure–response relationships of obinutuzumab still n...

Descripción completa

Detalles Bibliográficos
Autores principales: Gibiansky, E, Gibiansky, L, Carlile, D J, Jamois, C, Buchheit, V, Frey, N
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2014
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4474170/
https://www.ncbi.nlm.nih.gov/pubmed/25353187
http://dx.doi.org/10.1038/psp.2014.42

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4474170/
https://www.ncbi.nlm.nih.gov/pubmed/25353187
http://dx.doi.org/10.1038/psp.2014.42

Ejemplares similares